Droia Oncology Ventures

Droia Oncology Ventures (Droia Ventures ) is a Belgian life-sciences venture capital firm founded in 2011 and based in Zaventem, Flemish Brabant, Belgium (Brussels area), focused on the development of oncology therapies and early-stage cancer-drug-development companies. The firm was founded by Co-Founders Luc Dochez (Managing Partner; serial biotech entrepreneur and industry veteran; previously at TiGenix and various European biotech companies) and Arnaud Ausset alongside partners, and has evolved from a single-thematic-oncology-focused fund into a broader European life-sciences investor. Droia has raised multiple institutional funds (Droia Oncology Ventures I / DOV I in 2011, Droia Oncology Ventures II / DOV II, Droia Fund III in 2020 at approximately EUR 140 million, Droia Fund IV in 2023 at approximately EUR 165 million) with aggregate AUM approaching or exceeding EUR 400 million across vintages. The firm operates across European and U.S. biotechnology / oncology / precision-medicine investments. Notable portfolio companies include Blacksmith Medicines, Triumvira Immunologics, Modifi Biosciences, Aktis Oncology, various other European and U.S. cancer-drug-development companies aEUR" producing multiple acquisitions and IPO exits.